InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,309.79
(
0.10%
)
US TECH 100
18,372.40
(
0.30%
)
Dow Jones
38,915.10
(
-0.40%
)
Brent Oil
83.88
(
1.24%
)
Bitcoin
68,353.98
(
-1.50%
)
Post# of 251947
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119695
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Wednesday, 05/27/2020 11:38:58 AM

Wednesday, May 27, 2020 11:38:58 AM

Post# of 251947
IRWD -12% on discontinuation of MD-7246 in IBS-D:

https://www.businesswire.com/news/home/20200527005251/en

Ironwood Pharmaceuticals…today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D). The Phase II trial did not meet its primary or key secondary endpoints. Based on these findings, Ironwood and AbbVie plan to discontinue the development of MD-7246.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up